Crohn’s disease

03/12/2014 - 11:00

New-onset Crohn’s disease is characterized by changes in the populations of gastrointestinal bacteria. This involves reduction in abundance of beneficial, anti-inflammatory microbes and increases in bacteria that promote processes such as inflammation and complications such as colorectal carcinoma. These are the findings of a large new multi-centre North American study to be published in the journal Cell Host and Microbe on March 12th. Furthermore, the study finds that the use of antibiotics can increase the microbial imbalance, tilting it further towards pathogenic organisms.


08/22/2013 - 10:19

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn’s disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).


11/01/2012 - 09:02

Crohn’s disease (CD) and ulcerative colitis (UC) – inflammatory diseases of the gastrointestinal tract – have puzzled the scientific community for decades. Ten years ago, researchers recognized that both genes and the environment contributed to these diseases but knew little about precisely how and why illness occurred. To begin to narrow in on the key pathways involved, they would need thousands of patients’ samples, millions of data points, and the commitment of physicians and scientists at dozens of institutions.

10/17/2012 - 17:49

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at the University of California San Diego, School of Medicine.  The study will appear in the October 18, 2012 issue of the New England Journal of Medicine (NEJM).

03/19/2012 - 11:10

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn’s disease, a form of inflammatory bowel disease (IBD).  CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

03/14/2012 - 09:57

Many children with Crohn’s disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement network, ceased to have symptoms and no longer needed to take steroids for disease management. These are the findings from a study appearing in Pediatrics that examined the network’s quality improvement efforts and their impact on outcomes. In this study, the proportion of children with Crohn’s disease in remission increased from 55 percent to 68 percent, with a similar improvement in ulcerative colitis patients.